Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Jun;22(6):e270-e280.
doi: 10.1016/S1470-2045(20)30725-7. Epub 2021 Mar 31.

8th European Conference on Infections in Leukaemia: 2020 guidelines for the use of antibiotics in paediatric patients with cancer or post-haematopoietic cell transplantation

Thomas Lehrnbecher  1 , Dina Averbuch  2 , Elio Castagnola  3 , Simone Cesaro  4 , Roland A Ammann  5 , Carolina Garcia-Vidal  6 , Jukka Kanerva  7 , Fanny Lanternier  8 , Alessio Mesini  3 , Malgorzata Mikulska  9 , Dorothea Pana  10 , Nicole Ritz  11 , Monica Slavin  12 , Jan Styczynski  13 , Adilia Warris  14 , Andreas H Groll  15 ; 8th European Conference on Infections in Leukaemia
Affiliations
Review

8th European Conference on Infections in Leukaemia: 2020 guidelines for the use of antibiotics in paediatric patients with cancer or post-haematopoietic cell transplantation

Thomas Lehrnbecher et al. Lancet Oncol. 2021 Jun.

Abstract

Paediatric patients with cancer and those undergoing haematopoietic cell transplantation are at high risk of bacterial infections. The 8th European Conference on Infections in Leukaemia (ECIL-8) convened a Paediatric Group to review the literature and to formulate recommendations for the use of antibiotics according to the European Society of Clinical Microbiology and Infectious Diseases grading system. The evaluation of antibacterial prophylaxis included mortality, bloodstream infection, febrile neutropenia, emergence of resistance, and adverse effects as endpoints. Initial antibacterial therapy and antibiotic de-escalation or discontinuation focused on patients with a clinically stable condition and without previous infection or colonisation by resistant bacteria, and on patients with a clinically unstable condition or with previous infection or colonisation by resistant bacteria. The final considerations and recommendations of the ECIL-8 Paediatric Group on antibacterial prophylaxis, initial therapy, and de-escalation strategies are summarised in this Policy Review.

PubMed Disclaimer

Conflict of interest statement

Declaration of interests TL reports unrestricted research support from Gilead Sciences; is a consultant for Gilead Sciences, Merck Sharp and Dohme, Pfizer, Astellas, and Roche; and serves at the speakers' bureau of Gilead Sciences, Merck Sharp and Dohme, Astellas, Pfizer, and GlaxoSmithKline. DA reports research support from Merck Sharp and Dohme; was a consultant for Pfizer; and served at the speakers' bureau of GlaxoSmithKline. EC is a consultant for Angelini and Ferrer. CG-V reports research grants from Gilead Sciences and Merck Sharp and Dohme; research grants from the Spanish Ministerio de Sanidad, Consumo y Bienestar Social, the Instituto de Salud Carlos III in Madrid, Spain, the European Regional Development Fund, and the European Institute of Innovation and Technology; and served at the speakers' bureau of Gilead Sciences, Merck Sharp and Dohme, Novartis, Pfizer, Janssen, and Lilly. JK is a consultant for Bayer. FL served at the speakers' bureau of Gilead Sciences and Basilea. MM is a consultant for and served at the speakers' bureau of Pfizer, Gilead Sciences, Merck Sharp and Dohme, Janssen, and Biotest. MS reports research support from Gilead Sciences, Merck Sharp and Dohme, and F2G; and served on the speakers' bureau of Merck Sharp and Dohme and Gilead Sciences. JS reports support from Gilead Sciences, Merck Sharp and Dohme, Astellas, Roche, Jazz Pharmaceuticals, and Pfizer; is a consultant for Gilead Sciences, Novartis, Pfizer, Merck Sharp and Dohme; and served at the speakers' bureau of Gilead Sciences, Merck Sharp and Dohme, Fresenius, and Astellas. AW is supported by the MRC Centre for Medical Mycology at the University of Exeter (grant MR/N006364/2); reports research support from Gilead Sciences; and served at the speakers' bureau of Gilead Sciences. AHG reports research support from Gilead Sciences, Merck Sharp and Dohme, and Pfizer; is a consultant for Amplyx, Astellas, Basilea, F2G, Gilead Sciences, Merck Sharp and Dohme, and Pfizer; and served at the speakers' bureau of Astellas, Basilea, F2G, Gilead Sciences, Merck Sharp and Dohme, and Pfizer. All other authors declare no competing interests.

Publication types

Substances

LinkOut - more resources